ARCALYST
Preclinical
RegeneronARCALYST is one of 38 therapeutic programs targeting Cryopyrin-Associated Periodic Syndrome. It is currently in Preclinical.
2
Indications
0
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
33 competitors in Gout
#DrugCompanyPhaseTrials
1Uloric
TakedaApproved
Zyloprim
Alnylam PharmaceuticalsApproved
Colcrys
Alnylam PharmaceuticalsApproved
Trexall
Alnylam PharmaceuticalsApproved
Arcoxia
NovartisApproved
Aleve
Alnylam PharmaceuticalsApproved
Otezla
AmgenApproved
Prevacid
TakedaApproved
Cellcept
RocheApproved
Rayos
RRoxane Laboratories
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for ARCALYST. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company